StockNews.com Initiates Coverage on Jaguar Health (NASDAQ:JAGX)

StockNews.com started coverage on shares of Jaguar Health (NASDAQ:JAGX) in a research note published on Sunday. The firm issued a sell rating on the biotechnology company’s stock.

Jaguar Health Stock Down 7.5 %

NASDAQ:JAGX opened at $0.16 on Friday. The company has a current ratio of 2.00, a quick ratio of 1.34 and a debt-to-equity ratio of 6.33. Jaguar Health has a one year low of $0.05 and a one year high of $1.22. The company has a fifty day moving average price of $0.08 and a 200 day moving average price of $0.18.

Institutional Investors Weigh In On Jaguar Health

Several hedge funds have recently made changes to their positions in JAGX. Renaissance Technologies LLC bought a new stake in shares of Jaguar Health in the 1st quarter worth approximately $1,079,000. Millennium Management LLC lifted its position in Jaguar Health by 152.3% in the second quarter. Millennium Management LLC now owns 533,153 shares of the biotechnology company’s stock worth $157,000 after purchasing an additional 321,795 shares during the period. Bank of New York Mellon Corp lifted its position in Jaguar Health by 507.3% in the first quarter. Bank of New York Mellon Corp now owns 169,749 shares of the biotechnology company’s stock worth $120,000 after purchasing an additional 141,796 shares during the period. Vanguard Group Inc. boosted its stake in Jaguar Health by 141.7% during the third quarter. Vanguard Group Inc. now owns 192,335 shares of the biotechnology company’s stock worth $50,000 after buying an additional 112,770 shares in the last quarter. Finally, Virtu Financial LLC increased its holdings in Jaguar Health by 76.1% in the 1st quarter. Virtu Financial LLC now owns 229,270 shares of the biotechnology company’s stock valued at $162,000 after buying an additional 99,073 shares during the period. Institutional investors own 12.04% of the company’s stock.

Jaguar Health Company Profile

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.